The company presented data demonstrating that ADHD patients with mutations in nine genes had a clinically meaningful and statistically significant response to AEVI-001.
Grail plans to enroll up to 120,000 women who have been screened via mammogram, to train and validate its NGS-based early detection cancer test.
Gencurix aims to achieve US FDA 510(k) clearance for its GenesWell BCT breast cancer prognostic test next year.
At the AACR annual meeting, researchers presented results from the Phase II SUMMIT trial investigating the pan-HER-targeted therapy neratinib.
A trial of a drug that mimics a PCSK9 gene mutation doesn't quite meet expectations, both Nature News and Forbes say.
Angsana will support a Phase 2 basket trial for a tyrosine kinase inhibitor that targets tumors harboring TRK, ROS1, and ALK fusions.
Tempus will provide sequencing and analysis for glioblastoma patients in a clinical trial at Duke using engineered poliovirus as a treatment.
The multi-center precision medicine trial has matched approximately 700 patients to 24 treatment arms so far, but some arms appear to be falling short of their recruitment goal.
Genelex is hoping that a recently published randomized-controlled trial will help it get on better footing with Medicare.
Geneticure has raised around $1.1 million to fund the study, which may very well be the largest prospective RCT for personalization of high blood pressure treatment.
Dog DNA testing finds that some purebreds might not truly be purebreds, Inside Edition reports.
Mary Beckerle has returned as director of the Huntsman Cancer Institute, according to ScienceInsider.
Smithsonian Magazine reports that environmental DNA sampling can be used to track elusive organisms.
In Genome Research this week: repetitive satellite DNA in the fruit fly, transcriptome map assembly pipeline, and more.